NCT02389959View on ClinicalTrials.gov

Intranasal Bevacizumab for HHT-Related Epistaxis

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 4, 2014

Primary Completion Date

January 23, 2020

Study Completion Date

January 23, 2020

Conditions
HHTHereditary Hemorrhagic TelangiectasiaEpistaxisNose BleedsNasal Bleeding
Interventions
DRUG

Bevacizumab

Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose

DRUG

Placebo (Saline)

4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control

Trial Locations (1)

94305

Stanford University Department of Otolaryngology- Head and Neck Surgery, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT02389959 - Intranasal Bevacizumab for HHT-Related Epistaxis | Biotech Hunter | Biotech Hunter